HSE approves reimbursement for Friedreich's ataxia drug Skyclarys

The Irish Health Service Executive (HSE) has approved the reimbursement of Skyclarys, a treatment for the rare genetic condition Friedreich's ataxia. This decision follows advocacy efforts by affected families and marks a shift in access policy for high-cost orphan drugs in Ireland.